Biopharma video podcast

Rewrite the Rules

In this vodcast series, we aim to inspire not just you, but the entire biopharmaceutical community. With insights from leading scientists around the world, it's an invitation to reshape and rewrite the rules of your laboratory.

Featured episode

Plasmids and AAVs—a special relationship

with Ryan Hylands, Senior Technical Specialist, Analytical Development, Pharmaron

In this episode, we explore the relationship between plasmid DNA (pDNA) and viruses and discuss innovative approaches to analyze pDNA quality.

Access the latest episode now and stay updated on new releases:

Recently released episodes

Explore the potential of mRNA

with Jérémie Parot, PhD, Research Scientist, SINTEF

In this episode, we explore the difficulties faced when characterizing mRNA and the opportunities that mRNA research brings to medicine.

Handle with care: Ionizable lipids and impurities

with Adam Crowe, PhD, Sr. Manager, Analytical Development, Precision NanoSystems ULC (part of Cytiva)

In this episode, we take a deep dive into the importance of ionizable lipids in lipid nanoparticles (LNPs) and why new analytical workflows are needed for this expanding field.

Beyond mRNA: Why size of IVT RNA matters

with Rebecca Young, PhD, Sr. Scientist I, RNA Sciences, Aldevron

In this episode, we explore self-amplifying RNA (saRNA), its benefits and how R&D and process development teams utilize this new in vitro transcribed RNA.

Answering the question - what's under that peak?

with Kristen Nields, PhD, Senior Scientist, Janssen

In this episode, we explore the challenges in charge variant analysis and how to address the bottlenecks with new workflow approaches.

Dealing with surprises

with Tyler Heibeck, PhD, Principal Scientist, Sutro Biopharma

In this episode, we talk about the surprises and challenges encountered in drug development and how new analytical approaches may help find the answer.

Finding the spark through collaboration

with Mike McKinnon, Senior Scientist II, Novartis

In this episode, we discuss the challenges of new modalities and how new analytical methods can address the evolving challenges in biotherapeutic characterization.

Change your mindset to move medicine forward

with Anita Liu, Associate Principal Scientist, Merck

In this episode, we take a look at the benefits of intact protein analysis and how to address challenges with new drug modalities.

The team viral vectors

with Jill Bradley-Graham, PhD, Senior Scientist, Gene and Cell Therapy BioAnalytics, Sanofi

In this episode, we discuss why viral vector characterization is particularly challenging and how collaboration is key for newly emerging fields.

The “personality” of oligonucleotides

with Shane Karnik, Senior Laboratory Director, Aliri Bioanalysis

In this episode, we discuss what bioanalysis is and how bioanalysis of oligonucleotides differs from that of other modalities.

Solving the HCP puzzle with mass spectrometry

with Thomas Kofoed, PhD, Co-founder and CEO, Alphalyse

In this episode, we chat about host cell proteins (HCPs), the importance of their analysis in cell and gene therapy products and the challenges of this field.

On or off target? Looking beyond the expected

with Hugo Gagnon,  PhD, Chief Scientific Officer, Allumiqs

In this episode, we take a deep dive into what gene editing is and uncover why establishing analytics for gene editing is such a complex task.